ES2059880T3 - Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias. - Google Patents

Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.

Info

Publication number
ES2059880T3
ES2059880T3 ES90109883T ES90109883T ES2059880T3 ES 2059880 T3 ES2059880 T3 ES 2059880T3 ES 90109883 T ES90109883 T ES 90109883T ES 90109883 T ES90109883 T ES 90109883T ES 2059880 T3 ES2059880 T3 ES 2059880T3
Authority
ES
Spain
Prior art keywords
inflammatory diseases
treatment
stearidonic acid
acid
stearidonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109883T
Other languages
English (en)
Inventor
Michel Guichardant
Michel Rigaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2059880T3 publication Critical patent/ES2059880T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE UTILIZA EL ACIDO ESTEARIDONICO EN UNA COMPOSICION FARMACEUTICA PARA PREVENIR Y TRATAR LAS ENFERMEDADES DE ORIGEN INFLAMATORIO EN LOS MAMIFEROS . LA FUNCION DEL ACIDO ES DE INHIBIR LA BIOSINTESIS DE LOS LEUCOTRIENOS Y DE LOS ACIDOS HIDROXIEICOSATETRAENICOS FORMADOS POR LA ACCION DE LA 5-LIPOXIGENASA SOBRE EL ACIDO ARAQUIDONICO.
ES90109883T 1990-05-23 1990-05-23 Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias. Expired - Lifetime ES2059880T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90109883A EP0457950B1 (fr) 1990-05-23 1990-05-23 Utilisation de l'acide stéaridonique pour le traitement des maladies inflammatoires

Publications (1)

Publication Number Publication Date
ES2059880T3 true ES2059880T3 (es) 1994-11-16

Family

ID=8204025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109883T Expired - Lifetime ES2059880T3 (es) 1990-05-23 1990-05-23 Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.

Country Status (7)

Country Link
US (1) US5158975A (es)
EP (1) EP0457950B1 (es)
JP (1) JP3065710B2 (es)
DE (1) DE69004081T2 (es)
DK (1) DK0457950T3 (es)
ES (1) ES2059880T3 (es)
IE (1) IE65969B1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
DE4432633C2 (de) * 1994-09-14 1997-07-31 Singer Peter Dr Med Priv Doz Pharmazeutisches Präparat zur lokalen Behandlung von Schuppenflechte, Neurodermitis und Ekzem
US6340485B1 (en) 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
AU2972497A (en) * 1996-06-03 1998-01-05 Croda International Plc Treatment of oils
KR20060061409A (ko) * 1996-10-11 2006-06-07 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
US5855893A (en) * 1997-02-14 1999-01-05 Elizabeth Arden Co., Division Of Conopco, Inc. Trichodesma lanicum seed extract as an anti-irritant in compositions containing hydroxy acids or retinoids
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
EP2275101A1 (en) * 2001-05-14 2011-01-19 Martek Biosciences Corporation Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses
CN101072509A (zh) * 2002-03-08 2007-11-14 孟山都技术有限公司 炎症的治疗和预防
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
US20070098787A1 (en) * 2003-06-20 2007-05-03 Mochida Pharmaceutical Co., Ltd. Composition for preventing and treating varicose veins of lower extremities
DE602004021001D1 (de) * 2003-08-21 2009-06-18 Monsanto Technology Llc Fettsäuredesaturasen aus primula
CA2562548C (en) 2004-04-16 2019-08-20 Monsanto Technology Llc Expression of fatty acid desaturases in corn
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
MA39718A (fr) * 2014-04-09 2017-02-15 Dignity Sciences Ltd Compositions et méthodes d'utilisation de celles-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
EP0087865B1 (en) * 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Also Published As

Publication number Publication date
DE69004081D1 (de) 1993-11-25
DK0457950T3 (da) 1994-03-07
US5158975A (en) 1992-10-27
JPH04226915A (ja) 1992-08-17
IE911450A1 (en) 1991-12-04
DE69004081T2 (de) 1994-02-10
EP0457950A1 (fr) 1991-11-27
JP3065710B2 (ja) 2000-07-17
EP0457950B1 (fr) 1993-10-20
IE65969B1 (en) 1995-11-29

Similar Documents

Publication Publication Date Title
ES2059880T3 (es) Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
EE05148B1 (et) Rasvhapete terapeutilised kombinatsioonid
DK0607128T3 (da) Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
ES2056854T3 (es) Tiadiazinonas.
CO4960645A1 (es) Composicion farmaceutica de drogas antiinflamatorias no- esteroides y analogos de gaba y metodos para prevenir y tratar dano gastrointestinal, enfermedad inflamatoria del intestino irritable y sindrome de privacion del alcohol
IT1164550B (it) Prodotto medicinale da somministrare per via orale dotato di azione antiflogistica
ES2052645T3 (es) Acidos poliinsaturados con accion vasocinetica y formulaciones farmaceuticas y cosmeticas que los contienen.
FI893805A0 (fi) Fettsyrakomposition.
ATE146970T1 (de) Behandlung von entzündungen
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
DK1056452T3 (da) Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
FI863976A0 (fi) Terapeutisk komposition.
DK0572159T3 (da) Medikament til behandling af vulva dystrofi eller vaginal tørhed
MC2078A1 (fr) Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires
ES2064778T3 (es) Esteres de acidos poliacrilicos con grupos hidrocarburo-oxi alcoxilados de cadena larga y su aplicacion en cosmetica y aseo corporal.
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
IT1263957B (it) Impiego terapeutico del pirrolidon carbossilato di piridossina
MX9305887A (es) Uso de acido hialuronico y formas para evitar restenosis arterial.
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
DE68911049D1 (de) Therapeutische Verwendung des Isopropylesterderivates von Monosialogangliosiden bei Erkrankungen des Nervensystems, begleitet von Entzündungen.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2090806T3 (es) Acilsulfonamido- y sulfonamido-piridina-2-esteres de acidos carboxilicos, asi como sus piridina-n-oxidos, procedimientos para su preparacion y su utilizacion como medicamentos.
ES2163450T3 (es) Utilizacion de benzidamina en el tratamiento de estados patologicos causados por tnf.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 457950

Country of ref document: ES